Biotechnology News and Research

RSS

Evotec signs definitive agreement to acquire all shares in Kinaxo

Evotec AG today announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted drugs.

9 Feb 2011

Clinical Data reports $2.0 million revenue for third quarter 2011

Clinical Data, Inc. today announced operational and financial results for the third fiscal quarter ended December 31, 2010. The Company received approval from the U.S. Food and Drug Administration (FDA) of Viibryd™ for the treatment of adults with major depressive disorder (MDD) on January 21, 2011.

9 Feb 2011

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has initiated a Phase 2 clinical trial, following conclusion of a review by the United States Food and Drug Administration (FDA) of a protocol submitted by PolyMedix, to assess the safety and efficacy of its heptagonist, PMX-60056, in reversing heparin in patients undergoing Percutaneous Coronary Intervention (PCI) procedures.

9 Feb 2011

Repligen third quarter total revenue increases 26% to $7,068,000

Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.

9 Feb 2011

GeoVax opens second HIV clinical trial site at Alabama Vaccine Research Clinic

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today the opening of a second clinical trial site at the Alabama Vaccine Research Clinic (AVRC) of the University of Alabama at Birmingham (UAB) to expand the company's HIV therapeutic vaccine trial.

9 Feb 2011

BBSRC, EMBL-EBI applaud funding allocation for European Life-science Infrastructure for Biological Information

The Biotechnology and Biological Sciences Research Council (BBSRC) and the European Molecular Biology Laboratory's European Bioinformatics Institute (EMBL-EBI) welcome news that funding has been earmarked from the UK's Large Facilities Capital Fund for ELIXIR - the European Life-science Infrastructure for Biological Information - as announced today (09 February 2011).

9 Feb 2011

Eviagenics closes financing round for EUR 1.3 million to commercialize its technology platform

Eviagenics, a French biotech company, is pleased to announce the closing of a series A financing round to scale up its technical and commercial development. At this occasion the FCPR Emertec 4 managed by Emertec Management, CEA Investissement, and Genopole Premier Jour managed by CapDecisif Management provide a total contribution of EUR 1.3 million.

9 Feb 2011

QLT's Phase II olopatadine punctal plug delivery system trial demonstrates safety in allergic conjunctivitis patients

QLT Inc. today announced results from a Phase II proof-of-concept clinical trial for the olopatadine punctal plug delivery system (O‑PPDS).

9 Feb 2011

Sartorius reports consolidated sales revenue of 659.3 million for fiscal 2010

Sartorius, a leading international laboratory and process equipment provider, successfully closed the year 2010. Sales revenue and earnings substantially surpassed the year-earlier figures. Financial guidance for the Group, which was raised during the course of 2010, was met and even exceeded for some targets.

From Sartorius 9 Feb 2011

Circassia acquires global rights to novel topical therapeutic for psoriasis and atopic dermatitis

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has acquired the worldwide development and commercialization rights to the novel topical therapeutic for psoriasis and atopic dermatitis, PAP-1. Circassia acquired the rights to the proprietary molecule from Airmid Inc, for an undisclosed upfront sum plus milestone payments and royalties on future product sales.

9 Feb 2011

Vitrolife fourth quarter sales increases 20% to SEK 81 million

A quarter with record sales concluded a year that set the stage for an increased potential in growth.

9 Feb 2011

Elan and Boehringer Ingelheim enter global collaboration for antibody-based therapeutics

Elan plc and Boehringer Ingelheim today announced that they have entered into a global technical development and manufacturing agreement for antibody-based therapeutics.

9 Feb 2011

Aushon BioSystems enters diagnostic development collaboration with Peking University Cancer Hospital

Aushon BioSystems, Inc., a leading provider of multiplex immunoassay products and services announced that it has signed a letter of intent to enter into a diagnostic development collaboration with Peking University Cancer Hospital ("PUCH"), Beijing, China.

9 Feb 2011

Momenta receives US patent for methods of developing glatiramer acetate drug

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, announced today that on February 8, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,884,187, entitled "Analysis of Amino Acid Copolymer Compositions."

9 Feb 2011

The Arthritis Society awards $3.5 million grant for new research and training

Canada's largest non-government funder of arthritis research has announced more than $3.5 million for new arthritis research and training.

9 Feb 2011

Vical announces issuance of US patent for HSV-2 vaccine

Vical Incorporated announced today the issuance of U.S. Patent No. 7,879,339, assigned to Vical and the University of Washington, covering DNA vaccines for herpes simplex virus type 2.

9 Feb 2011

Medicago granted FDA clearance for clinical development of seasonal flu vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received Food and Drug Administration ("FDA") clearance for its phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine") clinical trial in the United States.

9 Feb 2011

New insight into AMD related blindness

more than 50 million worldwideA new study in the journal Nature has reported the pathology of blindness caused by age-related macular degeneration or AMD. This condition affects more than 50 million worldwide and is incurable. The researchers report that when an enzyme known as DICER1 stops functioning AMD starts to develop.

8 Feb 2011

ScinoPharm to be Clinical Data's sole API supplier of vilazodone hydrochloride during Viibryd's launch

ScinoPharm, a leading active pharmaceutical ingredient (API) and contract research and manufacturing (CRAM) service provider to the global pharmaceutical and biotechnology industry, will provide commercial manufacturing service of vilazodone hydrochloride active pharmaceutical ingredient (API) for Clinical Data, Inc.'s Viibryd™, a new drug entity recently approved by the United States Food and Drug Administration.

8 Feb 2011

PDL, UCB enter definitive settlement agreement to resolve all legal patent disputes

UCB SA, on behalf of its affiliate UCB Pharma S.A., and PDL BioPharma, today jointly announced that the companies have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to UCB's pegylated humanized antibody fragment, Cimzia, and PDL's patents known as the Queen et al. patents.

8 Feb 2011

Biotechnology News and Research

Evotec signs definitive agreement to acquire all shares in Kinaxo

Clinical Data reports $2.0 million revenue for third quarter 2011

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

Repligen third quarter total revenue increases 26% to $7,068,000

GeoVax opens second HIV clinical trial site at Alabama Vaccine Research Clinic

BBSRC, EMBL-EBI applaud funding allocation for European Life-science Infrastructure for Biological Information

Eviagenics closes financing round for EUR 1.3 million to commercialize its technology platform

QLT's Phase II olopatadine punctal plug delivery system trial demonstrates safety in allergic conjunctivitis patients

Sartorius reports consolidated sales revenue of 659.3 million for fiscal 2010

Circassia acquires global rights to novel topical therapeutic for psoriasis and atopic dermatitis

Vitrolife fourth quarter sales increases 20% to SEK 81 million

Elan and Boehringer Ingelheim enter global collaboration for antibody-based therapeutics

Aushon BioSystems enters diagnostic development collaboration with Peking University Cancer Hospital

Momenta receives US patent for methods of developing glatiramer acetate drug

The Arthritis Society awards $3.5 million grant for new research and training

Vical announces issuance of US patent for HSV-2 vaccine

Medicago granted FDA clearance for clinical development of seasonal flu vaccine

New insight into AMD related blindness

ScinoPharm to be Clinical Data's sole API supplier of vilazodone hydrochloride during Viibryd's launch

PDL, UCB enter definitive settlement agreement to resolve all legal patent disputes

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News